Smartleaf Asset Management’s NRX Pharmaceuticals NRXP Stock Holding History

Smartleaf Asset Management’s Portfolio NRXP Stock Details NRXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$7.3K	Buy	+2,500	New	+$8.88K	﹤0.01%	2566

Other funds holding NRXP

AdvisorShares Investments Bethesda, Maryland $796M AUM 17.24% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $77B AUM 19.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Prime Capital Investment Advisors Overland Park, Kansas $10.2B AUM 17.74% 1-Year Est. Return

Chicago Partners Investment Group Chicago, Illinois $5.45B AUM 19.52% 1-Year Est. Return

Global Retirement Partners San Rafael, California $7.1B AUM

Group One Trading Chicago, Illinois $73.3B AUM 63.67% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $84.4B AUM 20.16% 1-Year Est. Return

Smartleaf Asset Management's NRXP Position: Q3 2026 in Review

Smartleaf Asset Management opened a new position in NRX Pharmaceuticals (NRXP) in Q3 2026: 2,500 shares worth $7.3K. The stake represents ﹤0.01% of the portfolio and ranks #2566 among its holdings.

16 funds tracked by Wall St. Rank hold NRXP as of Q3 2026.

Smartleaf Asset Management held 2,500 shares of NRX Pharmaceuticals worth $7.3K as of Q3 2026.
NRX Pharmaceuticals was a new Smartleaf Asset Management position in Q3 2026.
NRX Pharmaceuticals made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q3 2026, its #2566 holding.
16 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q3 2026.

Based on Smartleaf Asset Management's 13F filing for Q3 2026, filed 10 Nov 2026.